Pfizer Expands 'Make in India' and Innovation Efforts

Pfizer Limited reaffirms commitment to India with increased manufacturing and R&D presence. Managing Director Meenakshi Nevatia highlights the expansion of operations, including initiatives in Chennai, Goa, and Gurugram, as well as collaborations with startups and new vaccination centers. The company aims to enhance healthcare access and adult vaccinations.

Meenakshi Nevatia, Managing Director of Pfizer Limited, has reiterated the company's commitment to expanding its footprint in India. In a notable move, nearly 70% of Pfizer's Indian-market products are now domestically manufactured, either at its Goa plant or through 18 local contract partners, demonstrating its dedication to the 'Make in India' initiative.

Pfizer is enlarging its research and development framework across India, with a significant presence of 1,500 employees in Chennai and a growing research center at IIT Madras. 'We are 100 per cent committed to India,' affirmed Nevatia in an ANI interview, underlining the pharmaceutical giant's strategy for bolstering its R&D, manufacturing, and export capacity.

The expansion includes shifting oncology products from Australia to Gujarat and the establishment of an analytics hub in Mumbai. Nevatia emphasized the importance of enhancing healthcare access and fostering innovation through Pfizer's support for startups in diagnostics and med tech. Pfizer's flagship INDovation program, supported by partnerships with government entities, announced its latest startup winners, reinforcing its commitment to healthcare innovation.

(With inputs from agencies.)